Larvol Delta - Biosyngen39s-rstinclass-CART-asset-targeting-solid-tumors-has-entered-pivotal-phase-II-trial-Phase-I-trial-data-debut-at-ESMO-2024-Annual-Congress

BRG01 - Biosyngen

https://www.prnewswire.com/news-releases/biosyngens-first-in-class-car-t-asset-targeting-solid-tumors-has-entered-pivotal-phase-ii-trial-phase-i-trial-data-debut-at-esmo-2024-annual-congress-302251709.html

Sep 18, 2024

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next